Arthur DeCillis

Dr. DeCillis brings over 20 years of experience in pharma, having worked on numerous successful oncology products. He currently serves as the president of DeCillis Consulting LLC, a company that provides oncology strategic, medical, and operational consulting services to the pharmaceutical and biotechnology industries. Prior to forming his own consulting practice, Arthur was the chief medical officer for Eleven Biotherapeutics, a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies.

Previously, Arthur was the Vice President of Clinical Research and then Vice President of Medical Affairs at Exelixis, an oncology-focused biotechnology company. Prior to this, Arthur served as Executive Director of Oncology Development at Novartis, responsible for Phase 2 and Phase 3 oncology development. Earlier in his career, Arthur held positions of increasing responsibility in oncology global clinical research at Bristol-Myers Squibb, attaining the position of Group Director. Dr. DeCillis has been involved in the development of several commercial drugs including Sprycel® (dasatinib), Afinitor® (everolimus), Farydak® (panobinostat), and Cabometyx® (cabozantinib).

Prior to his career in the biopharmaceutical industry, Arthur was a member of the National Surgical Adjuvant Breast and Bowel Project (NSABP), a National Cancer Institute clinical cooperative group at the University of Pittsburgh. He has served as a member of the American Society of Clinical Oncology working group on economic analysis in Phase 3 clinical trials and the National Cancer Institute common toxicity criteria review committee.

Dr. Arthur DeCillis holds a Doctor of Medicine degree from the University of Rochester School of Medicine, a Master of Science degree from the University of Pittsburgh and a Bachelor of Science degree from Lehigh University. He is a diplomate of the American Board of Internal Medicine and the National Board of Medical Examiners.